Aeolus Pharmaceuticals, Inc. (AOLS) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aeolus Pharmaceuticals, Inc. (AOLS) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 47/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Aeolus Pharmaceuticals, Inc. (AOLS) Resumen de Asistencia Médica y Tuberías
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in catalytic antioxidant compounds for biodefense and diseases like fibrosis, oncology, and CNS disorders. Their lead asset, AEOL 10150, addresses acute radiation syndrome, positioning them within a niche market of medical countermeasures and targeted therapies.
Tesis de Inversión
Aeolus Pharmaceuticals operates in a high-risk, high-reward sector, focusing on biodefense and niche disease treatments. The company's lead compound, AEOL 10150, targeting acute radiation syndrome, represents a significant potential value driver, contingent on successful clinical trials and regulatory approval. Further development of AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease, and AEOL 20415 for infectious diseases, could diversify the pipeline. However, the company's negative profit margin of -171.4% and gross margin of -38.8% highlight financial challenges. The company's small size and OTC listing also present liquidity and volatility risks. Investors should closely monitor clinical trial outcomes, regulatory milestones, and funding activities.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Aeolus Pharmaceuticals operates with a small team of 4 employees, indicating a lean operational structure.
- The company's lead compound, AEOL 10150, has completed two Phase I clinical trials, marking progress in its development as a medical countermeasure.
- Aeolus Pharmaceuticals is developing compounds for Parkinson's disease (AEOL 11114B, AEOL 11203, and AEOL 11207) and infectious diseases (AEOL 20415), expanding its therapeutic focus.
- The company's negative profit margin of -171.4% reflects significant expenses relative to revenue, typical for early-stage biopharmaceutical companies.
- Aeolus Pharmaceuticals has a negative Beta of -5.55, suggesting an inverse correlation with the market, although this may be less reliable due to its OTC status and limited trading volume.
Competidores y Pares
Fortalezas
- Proprietary platform of catalytic antioxidant compounds
- Lead compound (AEOL 10150) with completed Phase I clinical trials
- Focus on biodefense and niche disease treatments
- Potential for government contracts and partnerships
Debilidades
- Negative profit and gross margins
- Limited financial resources
- Small team and operational scale
- OTC listing with associated liquidity risks
Catalizadores
- Ongoing: Clinical trial progress for AEOL 10150 in treating acute radiation syndrome.
- Ongoing: Development of AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease.
- Ongoing: Advancement of AEOL 20415 for treating infectious diseases.
- Upcoming: Potential government contracts for biodefense medical countermeasures.
- Upcoming: Strategic partnerships with larger pharmaceutical companies.
Riesgos
- Ongoing: Negative profit and gross margins indicating financial instability.
- Potential: Clinical trial failures leading to loss of investment.
- Potential: Regulatory hurdles and delays in drug approval processes.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Potential: Funding challenges and potential for dilution of existing shareholders.
Oportunidades de crecimiento
- Development of AEOL 10150 for Acute Radiation Syndrome: The global market for medical countermeasures against radiation exposure is projected to grow, driven by increasing concerns over nuclear threats and accidents. Successful completion of clinical trials and regulatory approval for AEOL 10150 could provide Aeolus with a significant revenue stream. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory review, potentially spanning several years.
- Expansion into Parkinson's Disease Treatment: The market for Parkinson's disease therapeutics is substantial and growing, driven by an aging population. Aeolus' development of AEOL 11114B, AEOL 11203, and AEOL 11207 represents an opportunity to tap into this market. Success in clinical trials and subsequent commercialization could lead to significant revenue growth. The timeline for this expansion depends on the progress of drug development and regulatory approvals.
- Advancement of AEOL 20415 for Infectious Diseases: The global market for infectious disease treatments is driven by the emergence of new pathogens and the increasing prevalence of existing infections. Aeolus' development of AEOL 20415 provides an opportunity to address unmet needs in this market. Successful development and commercialization could lead to revenue growth. The timeline for this opportunity depends on clinical trial outcomes and regulatory approvals.
- Strategic Partnerships and Collaborations: Aeolus could pursue strategic partnerships with larger pharmaceutical companies or government agencies to accelerate the development and commercialization of its drug candidates. Such partnerships could provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. The timeline for securing such partnerships is uncertain and depends on the attractiveness of Aeolus' pipeline and the willingness of potential partners.
- Government Contracts for Biodefense: Given its focus on medical countermeasures, Aeolus could pursue government contracts for the development and supply of drugs to protect against nuclear, radiological, and chemical threats. Securing such contracts could provide a stable revenue stream and validate the company's technology. The timeline for securing government contracts depends on government priorities and procurement processes.
Oportunidades
- Advancement of AEOL 10150 through clinical trials and regulatory approval
- Expansion into Parkinson's disease and infectious disease treatments
- Strategic partnerships with larger pharmaceutical companies
- Government contracts for biodefense
Amenazas
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from larger pharmaceutical companies
- Funding challenges and dilution
Ventajas competitivas
- Proprietary platform of catalytic antioxidant compounds.
- Patents protecting drug candidates and technologies.
- Expertise in developing medical countermeasures.
- Specialized focus on niche disease treatments.
Acerca de AOLS
Founded in 1994 and based in Mission Viejo, California, Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing a platform of novel compounds. The company's primary focus is on creating medical countermeasures against nuclear, radiological, and chemical weapons, as well as treatments for diseases and disorders affecting the respiratory system, central nervous system, and oncology. Their lead compound, AEOL 10150, has completed two Phase I clinical trials and is being developed to combat the pulmonary sub-syndrome of acute radiation syndrome. It is also intended for use as a medical countermeasure against exposure to chemical vesicants and nerve agents. In addition to AEOL 10150, Aeolus is developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, and AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals operates primarily in the United States, focusing on specialized drug development within the biodefense and targeted therapy sectors. The company aims to address unmet medical needs through its innovative platform of catalytic antioxidant compounds.
Qué hacen
- Develop catalytic antioxidant compounds for medical countermeasures.
- Create treatments for acute radiation syndrome.
- Develop drugs for exposure to chemical vesicants and nerve agents.
- Research treatments for diseases of the respiratory system.
- Develop therapies for central nervous system disorders.
- Develop oncology treatments.
- Research treatments for Parkinson's disease.
- Develop therapies for infectious diseases.
Modelo de Negocio
- Develop novel pharmaceutical compounds.
- Conduct preclinical and clinical trials to evaluate drug safety and efficacy.
- Seek regulatory approval for drug candidates.
- Potentially commercialize approved drugs through partnerships or direct sales.
Contexto de la Industria
Aeolus Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in drug development technologies. Companies like Aeolus face competition from larger pharmaceutical firms and other specialty drug developers. The industry is also subject to evolving regulatory landscapes, impacting drug approval processes and market access. Aeolus' focus on biodefense and niche disease treatments positions it within a specialized segment of this broader market.
Clientes Clave
- Government agencies responsible for biodefense.
- Hospitals and healthcare providers.
- Patients suffering from targeted diseases.
Finanzas
Gráfico e información
Precio de la acción de Aeolus Pharmaceuticals, Inc. (AOLS): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para AOLS.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para AOLS.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para AOLS.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de AOLS en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Christopher Stanley
CEO
Christopher Stanley serves as the CEO of Aeolus Pharmaceuticals, Inc. His background includes experience in managing and leading small teams within the biopharmaceutical sector. He has been involved in the strategic direction of the company, overseeing the development of its pipeline of novel compounds. His expertise lies in guiding the company through the various stages of drug development, from preclinical research to clinical trials.
Historial: Under Christopher Stanley's leadership, Aeolus Pharmaceuticals has focused on advancing its lead compound, AEOL 10150, through clinical trials. He has also overseen the development of other compounds targeting Parkinson's disease and infectious diseases. His tenure has been marked by efforts to secure funding and partnerships to support the company's research and development activities.
Información del mercado OTC de AOLS
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aeolus Pharmaceuticals may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited operating history, may be thinly traded, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency
- Potential for fraud or manipulation
- Thin trading volume and wide bid-ask spreads
- Higher price volatility
- Limited regulatory oversight
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Completion of Phase I clinical trials for AEOL 10150
- Development of compounds for Parkinson's disease and infectious diseases
- Focus on biodefense and medical countermeasures
- Company has been in business since 1994
Lo Que los Inversores Preguntan Sobre Aeolus Pharmaceuticals, Inc. (AOLS)
¿Cuáles son los factores clave para evaluar AOLS?
Aeolus Pharmaceuticals, Inc. (AOLS) actualmente tiene una puntuación IA de 47/100, indicando puntuación baja. Fortaleza clave: Proprietary platform of catalytic antioxidant compounds. Riesgo principal a monitorear: Ongoing: Negative profit and gross margins indicating financial instability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de AOLS?
AOLS actualmente puntúa 47/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de AOLS?
Los precios de AOLS se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre AOLS?
La cobertura de analistas para AOLS incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en AOLS?
Las categorías de riesgo para AOLS incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Negative profit and gross margins indicating financial instability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de AOLS?
La relación P/E para AOLS compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está AOLS sobrevalorada o infravalorada?
Determinar si Aeolus Pharmaceuticals, Inc. (AOLS) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de AOLS?
Aeolus Pharmaceuticals, Inc. (AOLS) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.